



CIN No : L24239MH1987PLC043662

November 13, 2017

To,

**BSE Ltd.,**  
Listing Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street - Fort,  
Mumbai – 400 001

Ref.: BSE Scrip Code - 539730

**Subject: Outcome of Board Meeting**

Dear Sir / Madam,

In compliance to Regulation 33 of SEBI Listing Regulations, 2015; we wish to inform you that the Board of Directors of the Company, at its Meeting held on Monday, November 13, 2017, have considered and approved the Unaudited Financial Results of the Company for Quarter & Half year ended September 30, 2017 along with the Limited Review Report issued by M/s. Savla & Associates, Statutory Auditors of the Company; the copies of which are attached hereunder.

**Any Other Matter:**

Approval of Leave and License Agreement between the Factory plots of Fredna Enterprises with the plots of the Company at Palghar to facilitate the expansion of the manufacturing unit of the Company.

The Meeting of the Board Commenced at 2:00 P.M. and concluded at 6:15 P.M.

Kindly take the same on your Records.

Thanking you,

For **FREDUN PHARMACEUTICALS LIMITED**



**DIRECTOR**

Encl. - A/a

**Office Address:** Manoj Industrial Premises, G.D. Ambekar Marg, Wadala, Mumbai - 400 031, (INDIA)

**Factory Address:** 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar ( E), Dist: Palghar - 401 404.

Phone: 91-22-4031 8111 Fax: 91-22-4031 8133 E-mail: [business@fredungroup.com](mailto:business@fredungroup.com) Web: [www.fredungroup.com](http://www.fredungroup.com)



# Savla & Associates

CHARTERED ACCOUNTANTS

8/196, Guru Sevak Kutir, Station Road

Wadala (W), MUMBAI - 400 031.

PHONE : 24102526, 24112526

FAX : 24132121

## LIMITED REVIEW REPORT

### TO THE BOARD OF DIRECTORS OF FREDUN PHARMACEUTICALS LTD


26,Manoj Industries Premises,  
G.P.Ambekar marg, Wadala,  
Mumbai – 400 031.

1. We have reviewed the accompanying Statement of Unaudited standalone Financial Result of **FREDUN PHARMACEUTICALS LTD** for the Quarter ended September 30, 2017 except for the disclosures regarding 'Public Shareholding' and Promoter Group Shareholding which have been traced from disclosures made by the management and have not been audited by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Financial Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of Company personal and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 prescribed under section 133 of the Companies Act, 2013 and other recognized accounting policies to the extent applicable, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.



MUMBAI, November 13, 2017

FOR SAVLA & ASSOCIATES  
Chartered Accountants  
(Firm Registration No.109361W)

  
DEEPAK G. SAVLA  
(Partner)

Membership No. : 043901